- Home
- DLO vs MRUS Comparison
DLO vs MRUS Comparison
Compare DLO & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLO
- MRUS
- Stock Information
- Founded
- DLO 2013
- MRUS 2003
- Country
- DLO Uruguay
- MRUS Netherlands
- Employees
- DLO N/A
- MRUS N/A
- Industry
- DLO Business Services
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- DLO Consumer Discretionary
- MRUS Health Care
- Exchange
- DLO Nasdaq
- MRUS Nasdaq
- Market Cap
- DLO 2.5B
- MRUS 2.7B
- IPO Year
- DLO 2021
- MRUS 2016
- Fundamental
- Price
- DLO $8.70
- MRUS $43.06
- Analyst Decision
- DLO Hold
- MRUS Strong Buy
- Analyst Count
- DLO 9
- MRUS 13
- Target Price
- DLO $11.94
- MRUS $86.85
- AVG Volume (30 Days)
- DLO 690.8K
- MRUS 872.0K
- Earning Date
- DLO 05-14-2025
- MRUS 05-07-2025
- Dividend Yield
- DLO N/A
- MRUS N/A
- EPS Growth
- DLO N/A
- MRUS N/A
- EPS
- DLO 0.39
- MRUS N/A
- Revenue
- DLO $745,974,000.00
- MRUS $36,133,000.00
- Revenue This Year
- DLO $30.04
- MRUS $26.81
- Revenue Next Year
- DLO $26.70
- MRUS $23.85
- P/E Ratio
- DLO $22.31
- MRUS N/A
- Revenue Growth
- DLO 14.70
- MRUS N/A
- 52 Week Low
- DLO $6.58
- MRUS $33.19
- 52 Week High
- DLO $15.75
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- DLO 45.49
- MRUS 51.15
- Support Level
- DLO $7.61
- MRUS $33.19
- Resistance Level
- DLO $8.88
- MRUS $43.46
- Average True Range (ATR)
- DLO 0.49
- MRUS 3.53
- MACD
- DLO 0.13
- MRUS 0.34
- Stochastic Oscillator
- DLO 69.47
- MRUS 80.53
About DLO DLocal Limited
DLocal Ltd is focused on making the complex simple, redefining the online payment experience in emerging markets. Through its technology platform, One dLocal, the company enables global enterprise merchants to get paid (pay-in) and to make payments (pay-out) online in a safe and efficient manner. The company earns revenue from fees charged to merchants in connection with payment processing services for cross-border and local payment transactions. The company's geographical segments include Latin America and Non-Latin America with a majority of its revenue being generated from Brazil in Latin America region.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.